AnalystsInsight

Dan Leonard (RBC Capital): Analyst Track Record and Price‑Target Accuracy

How often Dan Leonard’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 697 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+1 new rating (GRAL)+1 stock newly covered

Key takeaways

  • Dan Leonard ranks #452 of 1,000 analysts in Exent’s scoring (4.8★).
  • 54.9% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 84 days; 57.1% of calls were up 12 months later.
  • Most‑covered stocks: QGEN, BIO, GH, NTRA.
  • Free on Exent: Dan Leonard’s full record, with ratings 3 days after publication.

Dan Leonard’s track record at a glance

Dan Leonard of RBC Capital ranks #452 of the 1,000 analysts Exent scores, with a 4.8★ rating and a focus on healthcare. Over a 7‑year lookback, 54.9% of Dan’s price targets were reached, 2.5 points above the 52.4% average across all analysts.

MetricDan LeonardAll analysts
Price‑target hit rate54.9%52.4%
Median days to hit target84 days91 days
Calls up after 12 months57.1%64.0%
Median 12‑month return of calls+7.7%+13.4%
Hit rate, last 2 years58.2%—
Average worst drop after a call−21.5%—
Ratings in the sample697—
Stocks covered33—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetDan Leonard
Under 30 days23.6%
30–90 days27.3%
90–180 days26.7%
Over 180 days22.4%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Dan Leonard covers most

StockRatings in the sample
QGEN36
BIO31
GH30
NTRA25
IQV24
ILMN21
CRL20
AVTR18

In the past year Dan’s ratings were 62% Buy, 38% Hold and 0% Sell.

Dan Leonard’s latest ratings

DateStockActionRatingPrice target
Sep 17, 2026GRALInitiated Coverage: HoldHold$84.00
Sep 1, 2026TXGInitiated Coverage: HoldHold$70.00
Sep 1, 2026RVTYInitiated Coverage: HoldHold$135.00
Sep 1, 2026MTDInitiated Coverage: HoldHold$1515.00
Aug 26, 2026AReiterated: BuyBuy$185.00
Aug 24, 2026WATReiterated: BuyBuy$475.00
Aug 12, 2026TECHReiterated: HoldHold$73.00
Aug 10, 2026ILMNReiterated: BuyBuy$230.00
Aug 6, 2026BIOReiterated: BuyBuy$390.00
Aug 6, 2026NTRARated: BuyBuy$350.00
Aug 4, 2026WATReiterated: BuyBuy$475.00
Jul 31, 2026GHRated: BuyBuy$200.00
  • Sep 17, 2026
    Stock
    GRAL
    Action
    Initiated Coverage: Hold
    Rating
    Hold
    Price target
    $84.00
  • Sep 1, 2026
    Stock
    TXG
    Action
    Initiated Coverage: Hold
    Rating
    Hold
    Price target
    $70.00
  • Sep 1, 2026
    Stock
    RVTY
    Action
    Initiated Coverage: Hold
    Rating
    Hold
    Price target
    $135.00
  • Sep 1, 2026
    Stock
    MTD
    Action
    Initiated Coverage: Hold
    Rating
    Hold
    Price target
    $1515.00
  • Aug 26, 2026
    Stock
    A
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $185.00
  • Aug 24, 2026
    Stock
    WAT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $475.00
  • Aug 12, 2026
    Stock
    TECH
    Action
    Reiterated: Hold
    Rating
    Hold
    Price target
    $73.00
  • Aug 10, 2026
    Stock
    ILMN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $230.00
  • Aug 6, 2026
    Stock
    BIO
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $390.00
  • Aug 6, 2026
    Stock
    NTRA
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $350.00
  • Aug 4, 2026
    Stock
    WAT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $475.00
  • Jul 31, 2026
    Stock
    GH
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $200.00

Dan’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Dan Leonard’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Dan Leonard ranks #452 of 1,000 with a 4.8★ rating. 54.9% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 57.1% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Dan Leonard’s success rate is 62.4% by the ranking source and 54.9% by Exent’s price-target hit-rate backtest, with a median of 84 days to reach a target.

Dan Leonard (RBC Capital) covers 33 stocks, mostly in healthcare. The most frequently rated are QGEN, BIO, GH, NTRA, IQV.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.